UMB, Isoprene enter into deal with Hoth Therapeutics

The University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc., part of the UM BioPark, announced Wednesday they have entered into a commercial evaluation sublicense and option agreement with Hoth Therapeutics Inc., a development-stage biopharmaceutical company. The agreement grants Hoth complete evaluation and option rights in the dermatology evaluation field to develop and commercialize therapeutic compounds for the treatment of ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *